KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Albemarle (ALB) Research & Development (2016 - 2025)

Albemarle (ALB) has disclosed Research & Development for 17 consecutive years, with $12.4 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Research & Development fell 40.09% year-over-year to $12.4 million, compared with a TTM value of $70.8 million through Jun 2025, down 19.06%, and an annual FY2025 reading of $51.4 million, down 40.73% over the prior year.
  • Research & Development was $12.4 million for Q2 2025 at Albemarle, down from $14.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $23.5 million in Q1 2024 and bottomed at $12.1 million in Q4 2021.
  • Average Research & Development over 5 years is $16.9 million, with a median of $16.1 million recorded in 2022.
  • The sharpest move saw Research & Development soared 38.14% in 2022, then plummeted 40.09% in 2025.
  • Year by year, Research & Development stood at $12.1 million in 2021, then surged by 51.41% to $18.4 million in 2022, then rose by 23.94% to $22.8 million in 2023, then dropped by 8.72% to $20.8 million in 2024, then crashed by 40.09% to $12.4 million in 2025.
  • Business Quant data shows Research & Development for ALB at $12.4 million in Q2 2025, $14.1 million in Q1 2025, and $20.8 million in Q2 2024.